4.4 Article

Oncofertility: insights from IVF specialistsa worldwide web-based survey analysis

Journal

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
Volume 36, Issue 5, Pages 1013-1021

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10815-019-01419-8

Keywords

Fertility preservation; IVF; IVF-Worldwide; Oncofertility; Survey; Cryopreservation

Funding

  1. Teva Pharmaceutical Industries Ltd. [TST_TPU_SRVS_2017_21763]

Ask authors/readers for more resources

PurposeThis research sought to understand IVF-physicians' knowledge of, experience with, and attitudes toward fertility preservation for cancer patients.MethodsA 35-question, self-report survey request was emailed to IVF providers who were registered on the IVF-Worldwide.com network (3826 clinics). Physicians submitted responses on the IVF-Worldwide.com website. Survey results were reported as a proportion of the responding clinics.ResultsSurvey responses were completed by 321 (8.4%) globally distributed IVF clinics, representing 299,800 IVF cycles. Of these clinics, 86.6% (278) performed fertility preservation, treating approximately 6300 patients annually. However, 18.4% of the centers reported that patients sought advice independently, without an oncologist's referral. Ovarian tissue cryopreservation was performed by 37.7% of the clinics, yet 52.6% considered the procedure experimental. IVM was performed by 16.5% of responding clinics. A majority (63.6%) of the clinics selected treatment protocols based on each patient's malignancy. Most respondents (76.3%) disagreed that fertility preservation was not yet successful enough to make it an available option. However, 44.2% believed that pregnancy rates following oocyte cryopreservation could not be determined because not enough oocyte cryopreservation patients had completed embryo transfer.ConclusionsMost clinics performed fertility preservation, tailoring protocols to each patient's disease and condition. Almost 20% of patients sought advice independently, indicating that more effort is needed to encourage oncologists to refer patients. Most survey respondents believed that data was not yet available on either live birth outcomes or the best protocol for each disease. Therefore, long-term study must continue, with the establishment of interim milestones and an outcome-tracking registry.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available